9 results found.

Hereditary Pancreatic Cancer, Intraductal Papillary Mucinous Neop Clinical Trial using dynamic contrast-enhanced magnetic resonance imaging

OHSU Knight Cancer Institute - Recruiting 18 years to 85 years.
- The Use of Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE MRI) in the Management of Pancreatic Cancer.
dynamic contrast-enhanced magnetic resonance imaging

Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Ca Clinical Trial using ipilimumab; gemcitabine hydrochloride; laboratory biomarker analysis

Northwestern University - Recruiting 18 years or older.
- Ipilimumab and Gemcitabine for Advanced Pancreas Cancer: A Phase Ib Study.
ipilimumab; gemcitabine hydrochloride; laboratory biomarker analysis

Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcin Clinical Trial using gemcitabine hydrochloride; dasatinib; erlotinib hydrochloride

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Study of Gemcitabine, Dasatinib and Erlotinib in Patients With Advanced Pancreatic Carcinoma.
gemcitabine hydrochloride; dasatinib; erlotinib hydrochloride

Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcin Clinical Trial using 6,8-bis(benzylthio)octanoic acid

Comprehensive Cancer Center of Wake Forest University - Recruiting 18 years or older.
- A Pilot Study: Open-Label Clinical Trial of CPI-613 in Patients With Metastatic Pancreatic Adenocarcinoma and Poor Performance Status.
6,8-bis(benzylthio)octanoic acid

Metastatic Pancreatic Cancer, or Pancreatic Cancer Clinical Trial using IMMU-107; placebo; Gemcitabine

Immunomedics, Inc. - Recruiting 18 years or older.
- An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1).
IMMU-107; placebo; Gemcitabine

Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcin Clinical Trial using dinaciclib; Akt inhibitor MK2206; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Trial of Dinaciclib (SCH727965) and MK-2206 in Metastatic Pancreatic Cancer With an Expansion Cohort in Advanced Pancreatic Cancer.
dinaciclib; Akt inhibitor MK2206; pharmacological study; laboratory biomarker analysis

Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcin Clinical Trial using alisertib; gemcitabine

University of California, Davis - Recruiting 18 years or older.
- Phase I Study of the Combination of MLN8237 and Gemcitabine in Advanced Solid Tumors With Emphasis on Pancreatic Cancer.
alisertib; gemcitabine

Pancreatic Cancer Stage II, or Pancreatic Cancer Stage III Clinical Trial using Neoadjuvant gemcitabine, capecitabine, and docetaxel; Gemcitabine, capecitabine, docetaxel followed by radiotherapy

Columbia University - Recruiting 18 years or older.
- Phase II Study: Neoadjuvant Gemcitabine, Docetaxel and Capecitabine Followed by Neoadjuvant Radiation Therapy With Gemcitabine and Capecitabine in the Treatment of Stage II and III Pancreatic Adenocarcinoma.
Neoadjuvant gemcitabine, capecitabine, and docetaxel; Gemcitabine, capecitabine, docetaxel followed by radiotherapy

Pancreatic Cancer Clinical Trial using capecitabine; cisplatin; epirubicin; gemcitabine

IRCCS San Raffaele - Recruiting 18 years to 75 years.
- Randomized Phase II-III Trial of Peri- or Post-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma.
capecitabine; cisplatin; epirubicin; gemcitabine